To investigate the effects of topically applied 17b-estradiol on the expression of extracellular matrix proteins in aged human skin, 17b-estradiol (0.01%) and its vehicle (70% propylene glycol, 30% ethanol) were applied to aged (68-82 y, eight females and five males) human buttock skin under occlusion for 2 wk (three times per week). Topical 17b-estradiol was found to increase the expression of type 1 procollagen mRNA and protein significantly in human aged skin in vivo. In addition, MMP-1 protein levels were reduced by topical 17b-estradiol. The expressions of TGFb1, TGF-b type II receptor, and Sma and Mad related (Smad)3 were increased by topical 17b-estradiol in aged human skin, and TGF-b1 neutralizing antibody inhibited 17b-estradiol-induced procollagen synthesis in cultured fibroblasts. We also found that the expressions of tropoelastin and fibrillin-1 mRNA and protein, and elastic fibers in aged skin were also increased by topical 17b-estradiol. Topical 17b-estradiol also increased keratinocyte proliferation and the epidermal thickness in aged human skin. We also observed the same effects of topical 17b-estradiol in young skin. In conclusion, our results suggest that topical 17b-estradiol treatment may improve the cutaneous function of aged human skin by improving the connective tissue and increasing epidermal thickness.
Cutaneous aging is the result of a combination of chronological and environmental (ultraviolet light, smoking, pollution) factors, and hormonal aging (Chung, 2003; Youn et al, 2003) . In aged skin, epidermal thinning, associated with reduced numbers of keratinocytes, may be observed histologically. The dermis also thins in aging skin, and results in a reduction in the amount and organization of connective tissue. Skin connective tissue is comprised primarily of fibrillar collagen bundles and elastic fibers. Collagen and elastin impart strength and resilience to skin, and their degeneration with aging causes skin to become fragile, and aged in appearance.
At present, most women in developed societies can expect to spend one-third or more of their lifetime in the postmenopausal period. During the menopausal years, the loss of estrogen production accelerates skin changes (Punnonen et al, 1987; Jemec and Serup, 1989) . The epidermis becomes thinner and re-epithelialization is retarded. The dermis also becomes thinner and loses its elasticity and tensile strength. The skin wrinkling and increased looseness of the skin after menopause correspond to changes in collagenous and elastic fibers, which have been reported to be owing to estrogen deficiency (Schmidt et al, 1994) . A significant reduction in skin collagen has been demonstrated to start at menopause. This menopause-related reduction shows a faster rate of loss during the initial postmenopausal period, and approximately 30% is lost in the first 5 y (Brincat et al, 1987b) . The average rate of loss of skin collagen has been reported to be 2.1% per postmenopausal year (Brincat et al, 1987a) .
Estrogen is a steroid hormone, which influences growth, differentiation, and the functions of many target tissue. There are three kinds of estrogen: E1 (estrone), E2 (estradiol), and E3 (estriol). E2 is the most functional estrogen during reproductive age, and is known to decrease abruptly after menopause. Skin tissue is an active target of estrogens, as demonstrated by estrogen receptor determinations (Schmidt et al, 1990) . Moreover, a higher estrogen receptor content has been reported in women (Ciocca and Roig, 1995) . It was found that estrogen replacement therapy improves the various symptoms of skin aging. For example, oral estrogen therapy caused thickening of the skin in postmenopausal women (Brincat et al, 1985; Maheux et al, 1994) , prevented the age-related reduction in cutaneous elasticity, thereby inhibiting skin slackness, and reducing the number and depth of wrinkles (Pierard et al, 1995; Dunn et al, 1997) . Also, the topical application of estrogen cream improved the external appearance of postmenopausal facial skin, elasticity and firmness markedly improved, and wrinkle depth and number decreased (Creidi et al, 1994; Schmidt et al, 1996) . These beneficial effects of estrogen may result from increased collagen or other matrix proteins. Many reports have found that skin collagen content increases in women on estrogen replacement (Brincat, 2000; Shah and Maibach, 2001 ). The molecular mechanism of estrogen-induced increased collagen content has not been investigated however.
Transforming growth factor (TGF-b) is a multifunctional cytokine that plays an important role in regulating cell growth, differentiation, and the biosynthesis of extracellular connective tissue (Massague, 1990 (Massague, , 1998 Piek et al, 1999) . In mammals, TGF-b1, -b2, and -b3 isoforms have been identified (Massague, 1990) . TGF-b initiate their cellular action by binding to cell surface receptors, TGF-b type I receptor (TbRI) and TGF-b type II receptor (TbRII). Upon binding, the activated TGF-b receptor complex transiently interacts with Sma and Mad related (Smad) proteins, intracellular signal transducers, which propagate TGF-b signals (Massague, 1998) . TGF-b is known to stimulate fibroblast proliferation in the dermis and induces the synthesis and secretion of the major extracellular matrix (ECM) proteins (Massague, 1998; Piek et al, 1999) . In addition, TGF-b downregulates the expressions of proteolytic enzymes, such as collagenase and stromelysin, which degrade extracellular matrix proteins (Eickelberg et al, 1999; Hall et al, 2003) . It has been reported that estrogen increases the production of TGF-b, and that this inhibits bone resorption in human osteoblast-like cells (Oursler et al, 1991) and rat bone (Yang et al, 1996) . It has also been reported that aging in healthy females is associated with a reduced rate of cutaneous wound healing and that TGF-b1 levels are reduced in the wound. In addition, it was found that the topical application of estrogen accelerates cutaneous wound healing by increasing TGF-b1 secretion by dermal fibroblasts in ovariectomized young female rodents (Ashcroft et al, 1997) .
Despite the important role of the TGF-b/Smad pathway in extracellular matrix regulation, no study has been conducted on the effects of topical 17b-estradiol on TGF-b signaling activation in aged human skin in vivo. Moreover, we still do not know the effects of topical estrogen on the amount and organization of elastic fibers in aged skin or on the expression of elastin and fibrillin-1, which are the major components of elastic fibers. Therefore, this study was undertaken to investigate the effects of topical 17b-estradiol on the expressions of type I procollagen, tropoelastin, fibrillin-1, and matrix metalloproteinase (MMP)-1 in aged human skin in vivo, and to observe changes in the expressions of 17b-estradiol-induced TGF-bs, TGF-b receptors, and Smad proteins. Our data suggest that topical 17b-estradiol improves cutaneous ECM alterations by stimulating the TGF-b/Smad pathway in aged human skin, and that these effects may ameliorate skin aging symptoms, such as skin wrinkling and loss of elasticity.
Results
Topical application of 17b-estradiol increased the expressions of type I procollagen mRNA and protein in aged human skin in vivo To investigate the effects of topical 17b-estradiol on type I procollagen mRNA and protein expression in aged skin, the buttock skins of elderly volunteers were treated with 0.01% 17b-estradiol or its vehicle (70% propylene glycol, 30% ethanol) solution three times per week for 2 wk (six times) under occlusion.
By RT-PCR analysis using total RNA extracted from punch-biopsied skin samples, we found that the levels of procollagen a1(I) mRNA in relation to glyceraldehyde-3-phosphate dehydragenase (GAPDH) mRNA were increased after topical 17b-estradiol (Fig 1a) . Topical 17b-estradiol significantly increased the expression of procollagen a1(I) mRNA by an average of 158.3% AE 16.5% (n ¼ 11, po0.001) versus vehicle-treated control skin (Fig 1a) .
We performed western blot analysis for type I procollagen protein using the total protein extracted samples of 17b-estradiol or vehicle-treated skin. The levels of type I procollagen protein in 17b-estradiol-treated skin were significantly higher by 261.7% AE 43.8% (n ¼ 13, po0.01) than in vehicle-treated skin (Fig 1b) . Interestingly, the increases in the level of type I procollagen by topical 17b-estradiol treatment in aged female skin (336.4% AE 55.7%, n ¼ 8) was significantly higher (po0.05) than in aged male skin (142.3% AE 22.1%, n ¼ 5). These results indicate that topical 17b-estradiol may increase the synthesis of type I procollagen in aged human skin in vivo regardless of gender, and that, however, this effect was significantly greater in aged women than aged men. Thus, it appears that reduced estrogen levels with aging may contribute to reduced procollagen synthesis in aged human skin in both aged women and aged men.
To localize and compare the expressions of type I procollagen protein in the 17b-estradiol or vehicle-treated skin, we performed immunostaining with two kinds of antibodies for type I procollagen. Anti-human procollagen type I Cpeptide (PIC) antibody stains strongly for intracellular procollagen protein (Fig 2c, d) , whereas anti-procollagen type 1 amino-terminal extension peptide (SP1.D8) antibody stains extracellular procollagen proteins, especially beneath the dermo-epidermal junction (Fig 2a, b) . We found that the extracellular and intracellular expressions of type I procollagen protein in the 17b-estradiol-treated skin (Fig 2b, d) were greater than in vehicle-treated skin (Fig 2a, c) . The number of type I procollagen-positive fibroblasts stained with PIC antibody in the upper dermis in 17b-estradiol-treated skin (57.5 AE 7.8 cells per Â 200 magnified microscopic field, n ¼ 6, po0.01) was significantly higher than in vehicle-treated skin (17.3 AE 3.2 cells, n ¼ 6) of the same individuals (Fig 2e) . In Masson's trichome stained section, collagen fiber bundles were increased and thickened in the upper dermis of 17b-estradiol-treated skin, compared with vehicletreated skin (Fig 2f) . In order to investigate the concentration-dependent effects of topical 17b-estradiol on the expression of type I procollagen expression in aged human skin, the buttock skins of elderly volunteers were treated with 0.001%, 0.003%, and 0.01% 17b-estradiol or its vehicle (70% propylene glycol, 30% ethanol) solution for a week (three times) under occlusion. By Quantitative realtime RT-PCR, we found that 0.003% and 0.01%, but not 0.001%, topical 17b-estradiol significantly increased the expression of procollagen a1(I) mRNA (n ¼ 3), compared with vehicle-treated control skin (Fig 2g) . We also found, by immunohistochemical staining, that extracellular and intracellular expressions of type I procollagen protein in the 0.003% and 0.01% 17b-estradiol-treated skin were increased, compared with vehicle-treated skin (Fig 2h) . This observation suggests that topical 17b-estradiol treatment can increase type I procollagen synthesis and restore collagen fiber bundles in aged human skin in vivo.
Topical application of 17b-estradiol reduced MMP-1 protein expression in aged human skin in vivo To investigate whether topical 17b-estradiol can regulate MMP-1 expression in aged skin, we compared MMP-1 protein expressions by western blot using the soluble protein fraction extracted from 17b-estradiol or vehicle-treated skin of the same individuals. We found that topical 17b-estradiol treatment reduced MMP-1 protein expression significantly by 76.9% AE 3.9% versus vehicle-treated skin, in five of ten elderly subjects (Fig 3) . The decreases in the level of MMP-1 by topical 17b-estradiol treatment were not different between aged female and male skin (data not shown). This result suggests that estrogen downregulation with aging may contribute to increased MMP-1 expression in aged human skin.
Topical 17b-estradiol increased TGF-b1 mRNA expression and protein in aged human skin in vivo The effect of topical 17b-estradiol on TGF-b1 mRNA expression was investigated by RT-PCR, using the total RNA extracted directly from the punch-biopsy samples. The application of 17b-estradiol (0.01%) for 2 wk to aged buttock skin increased the TGF-b1 mRNA level to 117.3% AE 8.8% versus vehicle-treated skin (Fig 4a, n ¼ 11, po0 .05). There tended to be higher expression of TGF-b1 mRNA induction in aged female skin, compared with aged male skin, but it was not statistically significant (data not shown). The PCR product was isolated, sequenced, and found to be identical to the TGF-b1 cDNA fragment (data not shown).
By immunohistochemical staining, we found that topical 17b-estradiol increased the expressions of TGF-b1, -b2, and -b3 proteins in the aged human skin (Fig 4b, n ¼ 5) . In control skin, TGF-b1 protein was present minimally in the epidermis and dermis, whereas TGF-b2 and -b3 were stained moderately in the lower epidermis and in some dermal cells (Fig 4b) . Topical 17b-estradiol increased not only TGF-b1 staining, which was primarily localized in the dermis, but also TGF-b2 and -b3 staining, which primarily localized in the epidermis. These results indicate that topical 17b-estradiol upregulates TGF-b1 expression in aged skin, which may increase the synthesis of procollagen and the inhibition of MMP-1 in aged skin.
Anti-TGF-b1 antibody inhibited 17b-estradiol-induced type I procollagen synthesis in cultured human dermal fibroblasts In order to investigate whether TGF-b1 mediates 17b-estradiol-induced type I procollagen synthesis, anti-human TGF-b1 antibody was added to a dermal fibroblast culture medium just before 17b-estradiol was added, and media were harvested 48 h later. Type I procollagen levels were measured in cell-free supernatants using a commercially available ELISA kit.
The 17b-estradiol (1 mM) was found to increase the synthesis of type I procollagen protein to 132.1% AE 2.2% (po0.01), compared with the control. On the other hand, TGF-b1 (10 ng per mL) increased type I procollagen protein to 162.7% AE 9.2% (po0.01), compared with the vehicle control. The addition of 1 or 3 mg per mL of antihuman TGF-b1 antibody inhibited 17b-estradiol-induced type I procollagen synthesis concentration-dependently to 119.9% AE 9.0% (p40.05) and 104.6% AE 8.4% (po0.05) of the vehicle-treated control, respectively (Fig 5) . These results suggest that TGF-b may mediate, at least in part, 17b-estradiol-induced procollagen synthesis in human fibroblasts.
The topical application of 17b-estradiol increased the expression of TbRII, but not of TbRI, in aged human skin in vivo It has been reported that the expressions of TbRI and TbRII are downregulated in aged fibroblasts in vitro, and that the expression of TbRII is also reduced in aged skin in vivo (Mori et al, 1998; Rittie and Fisher, 2002) . Therefore, we investigated whether 17b-estradiol application can af- Figure 1 The expression of type I procollagen mRNA and protein increased after topical 17b-estradiol application to aged human skin in vivo. Buttock skin of elderly volunteers (five men, mean age 76.2 y, age range 75-79 y; eight women, mean age 73.2 y, age range 62-78 y) were treated with 0.01% 17b-estradiol or its vehicle (70% propylene glycol, 30% ethanol) solution three times a week for 2 wk (six times) under occlusion. The skin samples were obtained by punch biopsy. (a) The levels of procollagen a1(I) mRNA were measured in the total RNA extracted from buttock skin (n ¼ 11) by RT-PCR. Data are expressed as ratios of procollagen a1(I) to GAPDH, and as percentage increases relative to vehicle-treated skin. (b) The levels of type I procollagen protein were measured in total proteins extracted from aged buttock skin (n ¼ 13) by western blot. Data are expressed as ratios of type I procollagen to b-actin, and as percentage increases relative to vehicle-treated skin. Values are means AE SEM. Insets show representative RT-PCR and western blot bands, respectively. ÃÃ po0.01, ÃÃÃ po0.001 versus vehicle-treated control skin.
fect the expressions of TbRII and TbRI. The effects of topical 17b-estradiol on TbRII and TbRI mRNA expression were investigated by RT-PCR, using the total RNA extracted directly from the punch-biopsy samples (n ¼ 10). Topical application of 17b-estradiol (0.01%) to skin increased the TbRII mRNA level by an average of 180% AE 57.1% (n ¼ 10, po0.05), compared with vehicle-treated control skin (Fig  6a) , but did not affect the TbRI mRNA level (data not shown). There was no significant difference in TbRII mRNA induction between aged female and male skin (data not shown). The PCR products were isolated, sequenced, and found to be identical to the TbRII and TbRI cDNA fragments (data not shown).
We found by immunohistochemical staining that topical 17b-estradiol upregulated TbRII protein in the epidermis and dermis of aged human skin (Fig 6b, n ¼ 7) . The immunoreactivity for TbRI protein was, however, unaffected by 17b-estradiol treatment (Fig 6b, n ¼ 7) . These results indicate Topical application of 17b-estradiol increased the expression of type I procollagen protein and collagen fibers in aged human skin in vivo. 17b-Estradiol (0.001%, 0.003%, 0.01%) or its vehicle (70% propylene glycol, 30% ethanol) were applied to the buttock skin of elderly subjects under occlusion. (a, b, h) The extracellular expression of type I procollagen was detected using SP1.D8 antibody, and (c, d, h) the intracellular expression of type I procollagen protein in fibroblasts was detected using PIC antibody by immunohistochemical staining. (e) The number of fibroblasts expressing type I procollagen protein in the upper dermis was counted. Values are means AE SEM per Â 200 field of six subjects. The photographs are representative of six subjects. ÃÃ po0.01. (f) Masson's trichome staining of collagen fiber bundles (n ¼ 5). (g) The levels of procollagen a1(I) mRNA were measured in the total RNA extracted from buttock skin (n ¼ 3) by real-time RT-PCR. that the 17b-estradiol treatment increased TGF signaling activity by upregulating TbRII expression.
Topical application of 17b-estradiol increased the expressions of Smad3 and Smad7 in aged human skin in vivo Smad transcription factors are intracellular mediators of TGF-b signaling and have been shown to mediate the effects of TGF-b on the deposition of extracellular matrix (Verrecchia and Mauviel, 2002) . Therefore, we investigated the effect of topical 17b-estradiol on Smad3 expression, which is a receptor-activated Smad and is directly activated by TGF-b to TbRII binding, and on Smad7 expression, which is an inhibitory Smad, which performs a negative feedback function in TGF-b signaling. Topical 17b-estradiol increased Smad3 mRNA to 191% AE 51.9% (Fig 7a, n ¼ 5 ) and induced Smad7 mRNA expression significantly to 127% AE 9.3% (Fig 7c, n ¼ 7, po0 .05) versus vehicle-treated skin. We also found that topical 17b-estradiol increased Smad3 protein to 113.6% AE 9.9% (Fig 7b, n¼ 7 ), but Smad7 protein was not detected by western blot analysis in this study (data not shown).
Figure 3
The expression of matrix metalloproteinase (MMP)-1 protein decreased after topical 17b-estradiol application to aged human skin in vivo. The expression of MMP-1 protein was measured by western blot using the soluble protein fraction extracted from the 17b-estradiol or vehicle-treated buttock skins of the same elderly individuals (n ¼ 10). ÃÃ po0.01, versus vehicle-treated control skin. Mean AE SEM. 17b-Estradiol-induced type I procollagen synthesis was inhibited by adding neutralizing TGF-b1 antibody to cultured human dermal fibroblasts. Neutralizing anti-human TGF-b1 antibody (1-3 mg per mL) was added to dermal fibroblast culture medium just before 17b-estradiol treatment (1 mM), and culture media were harvested 48 h later. Type I procollagen levels were measured in cell-free supernatants by ELISA. ÃÃ po0.05 versus vehicle-treated control fibroblasts, y po0.05 versus 17b-estradiol-treated fibroblasts. Values are means AE SEM. The graph shown is representative of three experiments.
Topical 17b-estradiol increased the expressions of tropoelastin and fibrillin-1 in aged human skin in vivo We also investigated the effects of topical 17b-estradiol on the mRNA expression of tropoelastin and fibrillin-1 in aged human skin in vivo. RT-PCR was performed using the total RNA extracted from the punch-biopsied samples of 17b-estradiol and vehicle-treated skin. Tropoelastin mRNA expression was increased to 122% AE 12.4% (n ¼ 11, po0.05) in 17b-estradiol-treated skin, compared with vehicle-treated skin (Fig 8a) . Topical 17b-estradiol also increased the expression of fibrillin-1 mRNA to 182.1% AE 44% (n ¼ 11, po0.01), compared with vehicle-treated skin (Fig 8b) . There were no significant differences in tropoelastin and fibrillin-1 mRNA induction between aged female and male skin (data not shown).
Immunohistochemical staining showed that anti-tropoelastin and anti-fibrillin-1 antibodies stained fine ascending fibers (oxytalan fibers) in the papillary dermis beneath the dermoepidermal junction, and elaunin and elastic fibers in the mid-dermis (Fig 8c, d) . We observed that the immunoreactivities of tropoelastin and fibrillin-1 protein were increased by 17b-estradiol treatment in aged skin versus vehicle-treated skin, and most of the immunoreactivity of both proteins was present in association with elastic fibers. The numbers and lengths of elastin-and fibrillin-1-immunoreactive elastic fibers were greater in 17b-estradiol-treated skin than in the vehicle-treated skin of the same individuals (Fig 8c, d) . This observation suggests that topical 17b-estradiol treatment can increase and restore elastic fibers in aged human skin in vivo. The topical application of 17b-estradiol-induced keratinocyte proliferation and increased epidermal thickness in aged human skin in vivo We found that topical 17b-estradiol increased the number of Ki-67 positive keratinocytes in the basal cell layer of the epidermis and increased epidermal thickness, compared with vehicletreated skin (Fig 9) . The topical application of 0.01% 17b-estradiol to aged human skin (three times a week for 2 wk under occlusion) increased the number of Ki-67 positive keratinocytes in the basal cell layer significantly (145 AE 48.7 cells per mm, n ¼ 5, po0.01) versus control skin (74 AE 4.2 cells per mm) (Fig 9a, b) . And, the epidermal thickness of the 17b-estradiol treated skin was also significantly greater to 133.8% AE 10.4% (n ¼ 5, po0.05) versus control skin (Fig 9a, c) . These results indicate that topical 17b-estradiol can stimulate keratinocyte proliferation in aged human skin, and that this results in a greater epidermal thickness in vivo.
The effects of topical 17b-estradiol in young human skin in vivo In order to investigate whether topical 17b-estradiol is also effective in young skin or not, the buttock skins of young volunteers were treated with 0.01% 17b-estradiol or its vehicle (70% propylene glycol, 30% ethanol) solution three times per week for 2 wk (six times) under occlusion.
Topical 17b-estradiol significantly increased the expression of procollagen a1(I) mRNA by an average of 263.7% AE 65.0% (n ¼ 4, po0.05) (Fig 10a) , and the number of type I procollagen-positive fibroblasts in the upper dermis in 17b-estradiol-treated skin was significantly increased than in the case of vehicle-treated skin of the same young individuals (Fig 10d) . Topical 17b-estradiol increased the mRNA expression of tropoelastin (117.3% AE 21.6%, n ¼ 4) (Fig 10b) and fibrillin-1 (156.3% AE 35.8%, n ¼ 4, po0.05) (Fig 10c) in 17b-estradiol-treated young skin, compared with vehicle-treated skin. The numbers and lengths of elastin-and fibrillin-1-immunoreactive elastic fibers were increased in 17b-estradiol-treated young skin, compared with the vehicle-treated skin of the same individuals (Fig 10e, f) . Topical 17b-estradiol increased significantly the expressions of TGF-b1 (Fig 11a) , TbRII (Fig 11b) , Smad3 (Fig 11c) , and Smad7 (Fig 11d) in young human skin.
Discussion
The skin aging process in the sun-protected skin of the elderly results in a loss of collagen and increased MMP-1 expression Chung et al, 2002) . We found that topical 17b-estradiol applied to aged human skin increased the expressions of type I procollagen mRNA and protein. Although there were individual variations of responses to estradiol, 0.003% and 0.01%, but not 0.001%, Figure 10 Topical 17b-estradiol increased the expressions of type I procollagen, tropoelastin and fibrillin-1 in young human skin in vivo. The levels of (a) type I procollagen, (b) tropoelastin, and (c) fibrillin-1 mRNA were measured in total RNA extracted from the 17b-estradiol or vehicle-treated buttock skin of the same young individuals by RT-PCR (n ¼ 4). Data are expressed as ratios of type I procollagen, tropoelastin, or fibrillin-1 to GAPDH and as percentage increases relative to vehicle-treated skin. The values shown are means AE SEM. Insets show a representative RT-PCR. Ã po0.05, Immunohistochemical staining of (d) type I procollagen, (e) tropoelastin, and (f) fibrillin-1. The photographs are representative of four young subjects. estradiol significantly increased the type I procollagen mRNA and protein expression in a concentration-dependent manner. 0.003% of estradiol tended to increase type I procollagen expression more than 0.01%. Our results are consistent with previous reports, which demonstrate that topical and systemic estrogen therapy can increase the skin collagen content, and help maintain skin dermal thickness and reduce skin wrinkling (Creidi et al, 1994; Maheux et al, 1994) . Climacteric skin aging is an entity distinct from intrinsic aging and photoaging. It is well known that the amount of skin collagen declines in the years following menopause owing to estrogen deficiency (Brincat et al, 1987a; Castelo-Branco et al, 1994) . Moreover, this postmenopausal reduction in skin collagen content may aggravate facial wrinkle formation in postmenopausal women (Youn et al, 2003) . This menopause-related decrease of collagen is not limited to skin, but is also observed in the bone and urinary tract, and contributes to the pathogeneses of osteoporosis and stress incontinence (Brincat et al, 1987b) . Furthermore, we observed that topical 17b-estradiol stimulated the synthesis of type I procollagen synthesis much more so in aged female skin. Our data suggest that the abrupt estrogen level reduction in postmenopausal women may accelerate age-dependent reduced collagen synthesis, leading to greater collagen deficiency in elderly women than in men; conversely, the response rate to topical 17b-estradiol treatment may be more rapid and prominent in postmenopausal women than in men. On the other hand, we could not see any significant differences between females and males in the other measurements, including MMP, TGF-b, TbRII, tropoelastin, and fibrillin-1. This discrepancy may be owing to the small number of volunteers of male and females who participated in each experiment, but further study is necessary to investigate these differences.
TGF-b is a major regulator of the synthesis of several extracellular matrix proteins. TGF-b has been shown to upregulate the production of type I, III, and VII collagens (Uitto et al, 1979; Massague, 1998; Vindevoghel et al, 1998) , and fibronectin (Hocevar et al, 1999) , and to regulate the expressions of several MMP including MMP-1, -2, -3, and -13 (Kubota et al, 1991; Uria et al, 1998) . TGF-b1 has also been shown to be downregulated in in vitro aged fibroblasts and in aged skin in vivo (Zeng et al, 1996; Mori et al, 1998; Rittie and Fisher, 2002) . Therefore, it is reasonable to speculate that the aging-related impairment of the TGF-b/Smad pathway may play a role in reducing collagen synthesis and increasing MMP-1 expression, and that 17b-estradiol-induced collagen synthesis and MMP-1 inhibition occur through the stimulation of TGF-b signaling by topical 17b-estradiol. In this study, we found that the topical application of 17b-estradiol increased the expression of TGF-b1 in aged human skin, and that neutralizing anti-TGF-b1 antibody can prevent increased type I procollagen production by 17b-estradiol in cultured fibroblasts. Our results indicate that the increased level of TGF-b1 by topical 17b-estradiol in aged human skin may mediate 17b-estradiol-induced collagen synthesis.
TGF-b initiates its signals by interacting with its receptors. The binding of TGF-b to TbRII results in the formation of a heteromeric complex between TbRI and TbRII, which results in the phosphorylation of TbRI by TbRII. Binding of TGF-b to TbRII is the first critical step in the TGF-b signaling cascade, because TbRI does not bind TGF-b directly (Laiho et al, 1991; Wrana and Attisano, 2000) . TbRI phosphorylates and activates the transcription factors Smad2 and Smad3, which then bind with their common partner, Smad4, to form a heteromeric complex that translocates to the nucleus, where it acts as a transcription factor (Verrecchia and Mauviel, 2002) . It has been reported that TbRI and TbRII are downregulated in in vitro aged fibroblasts and that the expression of TbRII is also reduced in aged skin (Zeng et al, 1996; Mori et al, 1998; Rittie and Fisher, 2002) . In this study, we found that topical 17b-estradiol increased the expressions of TbRII mRNA and protein in aged human skin. In contrast to TbRII, no significant changes were observed with respect to TbRI mRNA and protein expression after topical 17b-estradiol. Taken together, our data indicate that 17b-estradiol increases cellular responsiveness to TGF-b in aged human skin by two mechanisms, i.e., by increasing TGF-bs expression and by up-regulating TbRII. Further studies are needed to clarify the mechanisms by which 17b-estradiol upregulates TGF-b and TbRII expression. It has been shown that type I and type VII collagen gene expression upregulation by TGF-b involve the direct binding of Smad3 to specific Smad-binding elements in the respective promoters (Vindevoghel et al, 1998; Chen et al, 1999) . In particular, the transient overexpression of Smad3 in normal fibroblasts mimicked the effect of TGF-b on collagen gene transcription. In addition, inhibiting cellular Smad3 expression, or its binding to its cognate DNA recognition site within the type I collagen (COL1A2) promoter prevented the stimulation of COL1A2 transcription by TGF-b (Chen et al, 2000) . These finings indicate that endogenous Smad3 is necessary and sufficient for the stimulation of collagen production by TGF-b in skin fibroblasts. Importantly, Smad3 plays a part in multiple TGF-b-regulated responses, including the stimulation of collagens (Vindevoghel et al, 1998) , the synthesis of connective tissue growth factor (CTGF) (Holmes et al, 2001) , the suppression of MMP-1 gene expression (Yuan and Varga, 2001) , and the induction of MMP-13 expression (Leivonen et al, 2002) . Our results show that topical 17b-estradiol increases the expression of Smad3 in aged skin, suggesting that upregulation of Smad3 may be involved in the 17b-estradiol-elicited induction of type I procollagen and in the inhibition of MMP-1 expression in aged human skin in vivo.
The actions of TGF-b are antagonized by Smad7, which interacts with TbRI to prevent phosphorylation and activation of the receptor-regulated Smad2/3, thereby blocking TGF-b signaling. Moreover, the expression of Smad7 is induced by TGF-b itself, suggesting that the induction of endogenous Smad7 serves as a negative feedback function in TGF-b signaling (Whitman, 1997) . Therefore, it is possible that Smad7 expression in 17b-estradiol-treated aged skin is induced in response to TGF-b1 induction and Smad3 activation, to cause the autoinhibition of TGF-b signaling.
Elastin and fibrillin-1 are the main components of elastic fibers and confer the skin with an elastic property. Histologic findings of aged human skin show a general reduction in the extracellular matrix with reduced elastin and elastic fiber disintegration (Braverman and Fonferko, 1982) . In the present study, topical 17b-estradiol treatment increased tropoelastin and fibrillin-1 mRNA expression in aged human skin in vivo. We also found, by immunohistochemical staining, that the expressions of tropoelastin and fibrillin-1 proteins were increased by topical 17b-estradiol, and that this was mainly associated with elastic fibers. This report describes the stimulatory effects of topical 17b-estradiol on elastin and fibrillin-1 expression in aged skin. It was previously reported that TGF-b1 up-regulates elastin gene expression (Massague, 1998) and increases fibrillin-1 expression (Lorena et al, 2004) . Therefore, our data suggest that the 17b-estradiol-induced stimulation of TGF-b signaling may upregulate elastin and fibrillin-1 mRNA and protein expression in aged skin, and that this results in an increase and a restoration of elastic fibers in aged skin.
The epidermis of human skin becomes thinner with a loss of rete ridges with age. Moreover, it has been observed that oral estrogen therapy causes a thickening of the epidermis in castrated women (Brincat, 2000) . In this study, the topical application of 17b-estradiol to aged human skin increased the proliferation of epidermal keratinocytes, leading to a thickening of the epidermis. The biological effects of TGF-b are diverse and strongly dependent on cell type. In human skin, TGF-b inhibits the growth of epidermal keratinocytes and stimulates the growth of dermal fibroblasts (Massague, 2000) . Therefore, the 17b-estradiol-induced expression of TGF-b observed in this study may not be involved in the epidermal thickness caused by 17b-estradiol, and further study will be needed to understand the molecular mechanisms of epidermal thickness by topical 17b-estradiol. Recently, it has been suggested that 17b-estradiol stimulates keratinocyte proliferation by activation of ERK and also by modulating nuclear estrogen receptor levels (VerdierSevrain et al, 2004) .
We demonstrated that topical application of 17b-estradiol to young skin also increased the expression of extracellular matrix proteins, including type I procollagen, tropoelastin and fibrillin-1, and increased the TGF-b/Smad signaling by stimulating the expression of TGF-b1, TbRII, and Smad3 in the young skin. Estrogen affects target tissue function by binding to intracellular nuclear receptors, ER-a and ER-b, and also membrane-associated ER (Verdier-Sev-
Figure 12
Anti-skin aging effect of topical 17b-estradiol in aged human skin in vivo. rain et al, 2004) . Estrogens may maintain or even increase the cell function by modulating receptor levels, and estrogen depletion with aging may reduce the cell functions. Therefore, topical 17b-estradiol in both young and aged skin can stimulate the extracellular matrix protein expression by binding to ER, and the effects may be greater in aged skin by repairing estrogen deficiency in aged skin.
In conclusion, this study shows that the topical application of 17b-estradiol upregulates type I procollagen, tropoelastin, and fibrillin-1, and downregulates MMP-1 expression by stimulating the TGF-b/Smad signaling pathway, and that it increases the proliferation of epidermal keratinocytes in aged human skin in vivo (Fig 12) . Therefore, topical 17b-estradiol treatment may improve the cutaneous function of aged skin by improving the amounts and the organization of connective tissues and by increasing epidermal thickness.
Materials and Methods
Human skin samples A total of 16 elderly (eight men; age range 62-79 y, mean age 73.5 y; eight women; age range 68-82 y, mean age 73.2 y) and four young (four men; age range 31-34 y, mean age 33.3 y) Koreans, without current or prior skin diseases, provided skin samples. 17b-estradiol (0.001%-0.01%) or its vehicle (70% propylene glycol, 30% ethanol) was applied to the buttock skin three times a week for 2 wk under occlusion. Skin samples were obtained by punch biopsy at 2 d after the last treatment. Specimens for western blotting and RT-PCR analysis were snap frozen in liquid nitrogen, and specimens for immunohistochemical staining were oriented immediately in a cryomatrix (Shandon, Pittsburgh, Pennsylvania) and stored at À701C.
This study was conducted according to the Declaration of Helsinki Principles. All procedures involving human subjects received prior approval from the Seoul National University Institutional Review Board, and all subjects provided written informed consent.
Fibroblast cell culture Primary cultures of dermal fibroblasts were established from human adult foreskins in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal calf serum, 2 mM glutamine, penicillin (100 U per mL), and streptomycin (100 ug per mL) in a 371C humidified 5% CO 2 incubator. The fibroblasts were cultured until 90% confluent and then subcultivated. Cells cultured 4five passages were used for the experiments.
Immunohistochemical staining Serial sections of 5 mm thickness were mounted onto silane-coated slides (Dako, Glostrup, Denmark). Acetone-fixed frozen sections were stained with the following primary antibodies for 1h at room temperature: monoclonal anti-human PIC antibody (Takara, Shiga, Japan, 1:1000), monoclonal anti-procollagen type I aminoterminal extension peptide (SP1.D8) antibody (Developmental studies Hybridoma Bank, Iowa City, Iowa, 1:1000), anti-fibrillin-1 antibody (Neomarker, Fremont, California, 1:200), anti-tropoelastin antibody (EPC, Owensville, Missouri, 1:800), anti-TGF-b1, -b2 and -b3 antibody (Oncogene, San Diego, California, 1:100 dilution), anti-TbRI and anti-TbRII antibody (Oncogene, 1:100 dilution), and anti-Ki-67 antibody (Immunotech, Marseille Cedex, France, 1:1600). After rinsing in phosphate-buffered saline, the sections were visualized using an LSAB kit (Dako), which incorporates a biotinylated secondary antibody and horseradish-streptavidine conjugate. 3-Amino-9-ethylcarbazole was used as a chromogenic substrate. The sections were counterstained briefly in Mayer's hematoxylin. Control staining was performed with normal rabbit and mouse immunoglobulin and showed no immunoreactivity (data not shown).
The entire field of each section was examined at Â 400 magnification, the number of fibroblasts showing positive immunostaining for type I procollagen in the papillary dermis was counted, and the mean per Â 400 field calculated. The mean number of Ki-67 positive keratinocytes per millimeter in the epidermis was determined at Â 200, and the average thickness of the epidermis was determined using an image analyzer (IMTechnology, Daejeon, Korea).
Western blotting For western blotting, we used soluble protein extracted directly from the punch-biopsied skin samples, as described previously (Chung et al, 2000) . Skin samples were solubilized in lysis buffer (containing 1% Triton X-100, 150 mM NaCl, 5 mM ethylenediamine tetraacetic acid, 0.1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 mg per mL aprotinin, and 2 mg per mL leupeptin). After solubilizing, samples were incubated for 30 min on ice and then centrifuged at 13,000 Â g for 15 min at 41C. Total protein concentrations were measured using a BCA protein assay kit (Pierce, Rockford, Illinois). Type I procollagen, MMP-1 and Smad3 levels were determined using a monoclonal anti-procollagen type I aminoterminal extension peptide (SP1.D8, 1/10 dilution) antibody, anti-MMP-1 antibody (Oncogene,1/100 dilution), and anti-Smad3 antibody (Zymed, San Francisco, California, 1/ 100), respectively. The density of each band was quantified by densitometric analysis (AAB Soft Program, Fullerton, California).
RNA isolation and RT-PCR RT-PCR was performed as described previously (Seo et al, 2001) . Briefly, total RNA from human skin was extracted with Trizol (Invitrogen, Carlsbad, California) according to the manufacturer's protocol. Total RNA was reverse-transcribed using a 1st strand cDNA synthesis kit (Fermentas, Hanover, Maryland) for RT-PCR. The resulting specific cDNA fragments were amplified with 2.5 U of Taq polymerase (Bioneer, Daejeon, Korea) in Table I . RT-PCR primers 
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the presence of 20 pmol downstream and upstream primers for each target gene. The sequences of each primer and the sizes of the respective PCR products are shown at Table I . The cycle numbers used for tropoelastin (34 cycles), type I procollagen (25 cycle), Smad3 and Smad7 (28 cycles), TGF-b1 (18 cycles), TbRI (32 cycles), TbRII (32 cycles) fibrillin-1 (30 cycles), and GADPH (27 cycles) were in the linear amplification range (data not shown). For each sample studied, several negative controls were performed. Reaction products were subjected to electrophoresis on 1.2% agarose gel, visualized with EtBr, and signal strengths were quantified using a densitometric program (AAB Software). After normalizing versus GAPDH intensity, percentage increases were determined for each gene. Each experiment was repeated at least three times.
Quantitative real-time RT-PCR Total RNA was extracted from tissues using Trizol (Invitrogen), and 1 mg of total RNA was converted to cDNA using First Strand cDNA Synthesis Kit (Fermentas). Quantitation of procollagen a1(I) cDNA and endogeneous reference GAPDH cDNA was performed using a fluorescence detection method (ABI PRISM 7000 Sequence Detection System, PerkinElmer Applied Biosystems, Foster City, California). Sequence-specific PCR primer sets and TaqMan MGB probe (FAM dye-labeled) were purchased by Perkin-Elmer Applied Biosystems. Cycling conditions were 501C for 2 min, 951C for 10 min, followed by 40 cycles at 951C for 15 s and 601C for 1 min. To quantify the relative changes in gene expression between each sample, we used the comparative C T method, as previously described by Livak and Schmittgen (2001) . In the comparative C T method, the DC T mean value obtained in the vehicle-treated sample is 0 and the fold difference is 1.
ELISA assay for type I procollagen protein Type I procollagen protein levels in supernatant were determined by ELISA (Takara, Shiga, Japan). Supernatants of cultured dermal fibroblast treated with 17b-estradiol in the presence of anti-TGF-b1 antibody (0-3 mg per mL) were harvested, and stored at À701C.
Statistical analysis Statistical analyses were performed using the two-tailed, student t test or the paired t test. A p-value of less than 0.05 was considered statistically significant. All analyses were performed using Statistical Analysis Software (SAS, Cary, North Carolina).
